nodes	percent_of_prediction	percent_of_DWPC	metapath
Methocarbamol—CA1—Erythrocytes take up carbon dioxide and release oxygen—CA2—kidney cancer	0.0646	0.311	CbGpPWpGaD
Methocarbamol—CA1—Reversible hydration of carbon dioxide—CA2—kidney cancer	0.0513	0.247	CbGpPWpGaD
Methocarbamol—CA1—Reversible hydration of carbon dioxide—CA9—kidney cancer	0.0389	0.187	CbGpPWpGaD
Methocarbamol—Carvedilol—HIF1A—kidney cancer	0.0146	0.467	CrCbGaD
Methocarbamol—CA1—C-MYB transcription factor network—CD34—kidney cancer	0.0073	0.0352	CbGpPWpGaD
Methocarbamol—Carvedilol—VEGFA—kidney cancer	0.0059	0.188	CrCbGaD
Methocarbamol—Jaundice—Sorafenib—kidney cancer	0.00488	0.00641	CcSEcCtD
Methocarbamol—Thrombophlebitis—Paclitaxel—kidney cancer	0.00485	0.00637	CcSEcCtD
Methocarbamol—Coordination abnormal—Capecitabine—kidney cancer	0.00483	0.00635	CcSEcCtD
Methocarbamol—Flushing—Everolimus—kidney cancer	0.0048	0.00631	CcSEcCtD
Methocarbamol—Nasal congestion—Paclitaxel—kidney cancer	0.00461	0.00606	CcSEcCtD
Methocarbamol—Shock—Pazopanib—kidney cancer	0.00458	0.00602	CcSEcCtD
Methocarbamol—Injury—Paclitaxel—kidney cancer	0.00457	0.006	CcSEcCtD
Methocarbamol—Insomnia—Temsirolimus—kidney cancer	0.00447	0.00588	CcSEcCtD
Methocarbamol—Dysgeusia—Everolimus—kidney cancer	0.00441	0.0058	CcSEcCtD
Methocarbamol—Bradycardia—Sunitinib—kidney cancer	0.0044	0.00578	CcSEcCtD
Methocarbamol—Somnolence—Temsirolimus—kidney cancer	0.00439	0.00578	CcSEcCtD
Methocarbamol—Nystagmus—Doxorubicin—kidney cancer	0.00428	0.00563	CcSEcCtD
Methocarbamol—Vision blurred—Everolimus—kidney cancer	0.00425	0.00558	CcSEcCtD
Methocarbamol—Pain—Temsirolimus—kidney cancer	0.00423	0.00556	CcSEcCtD
Methocarbamol—Insomnia—Pazopanib—kidney cancer	0.00421	0.00554	CcSEcCtD
Methocarbamol—Flushing—Sorafenib—kidney cancer	0.00417	0.00548	CcSEcCtD
Methocarbamol—Somnolence—Pazopanib—kidney cancer	0.00414	0.00544	CcSEcCtD
Methocarbamol—Angioedema—Everolimus—kidney cancer	0.00412	0.00541	CcSEcCtD
Methocarbamol—Dyspepsia—Pazopanib—kidney cancer	0.0041	0.00539	CcSEcCtD
Methocarbamol—Vertigo—Vinblastine—kidney cancer	0.00406	0.00534	CcSEcCtD
Methocarbamol—Leukopenia—Vinblastine—kidney cancer	0.00405	0.00532	CcSEcCtD
Methocarbamol—Syncope—Everolimus—kidney cancer	0.00404	0.00531	CcSEcCtD
Methocarbamol—Leukopenia—Everolimus—kidney cancer	0.00403	0.0053	CcSEcCtD
Methocarbamol—Flushing—Sunitinib—kidney cancer	0.00401	0.00527	CcSEcCtD
Methocarbamol—Pain—Pazopanib—kidney cancer	0.00398	0.00523	CcSEcCtD
Methocarbamol—Thrombophlebitis—Capecitabine—kidney cancer	0.00398	0.00523	CcSEcCtD
Methocarbamol—Loss of consciousness—Everolimus—kidney cancer	0.00396	0.0052	CcSEcCtD
Methocarbamol—Convulsion—Vinblastine—kidney cancer	0.00392	0.00515	CcSEcCtD
Methocarbamol—Body temperature increased—Temsirolimus—kidney cancer	0.00391	0.00514	CcSEcCtD
Methocarbamol—Convulsion—Everolimus—kidney cancer	0.0039	0.00513	CcSEcCtD
Methocarbamol—Syncope—Erlotinib—kidney cancer	0.0039	0.00512	CcSEcCtD
Methocarbamol—Dysgeusia—Sorafenib—kidney cancer	0.00383	0.00503	CcSEcCtD
Methocarbamol—Loss of consciousness—Erlotinib—kidney cancer	0.00382	0.00502	CcSEcCtD
Methocarbamol—Flushing—Dactinomycin—kidney cancer	0.0038	0.00499	CcSEcCtD
Methocarbamol—CA1—C-MYB transcription factor network—GSTM1—kidney cancer	0.00376	0.0181	CbGpPWpGaD
Methocarbamol—Dysgeusia—Sunitinib—kidney cancer	0.00369	0.00484	CcSEcCtD
Methocarbamol—Amnesia—Capecitabine—kidney cancer	0.00367	0.00482	CcSEcCtD
Methocarbamol—Hypersensitivity—Temsirolimus—kidney cancer	0.00364	0.00479	CcSEcCtD
Methocarbamol—Shock—Everolimus—kidney cancer	0.00362	0.00475	CcSEcCtD
Methocarbamol—Angioedema—Sorafenib—kidney cancer	0.00357	0.0047	CcSEcCtD
Methocarbamol—Syncope—Sorafenib—kidney cancer	0.00351	0.00461	CcSEcCtD
Methocarbamol—Leukopenia—Sorafenib—kidney cancer	0.0035	0.0046	CcSEcCtD
Methocarbamol—Pruritus—Temsirolimus—kidney cancer	0.0035	0.0046	CcSEcCtD
Methocarbamol—Shock—Erlotinib—kidney cancer	0.00349	0.00459	CcSEcCtD
Methocarbamol—Jaundice cholestatic—Doxorubicin—kidney cancer	0.00348	0.00458	CcSEcCtD
Methocarbamol—Diplopia—Capecitabine—kidney cancer	0.00345	0.00453	CcSEcCtD
Methocarbamol—Angioedema—Sunitinib—kidney cancer	0.00344	0.00452	CcSEcCtD
Methocarbamol—Loss of consciousness—Sorafenib—kidney cancer	0.00344	0.00452	CcSEcCtD
Methocarbamol—Hypotension—Everolimus—kidney cancer	0.00344	0.00452	CcSEcCtD
Methocarbamol—Leukopenia—Sunitinib—kidney cancer	0.00337	0.00443	CcSEcCtD
Methocarbamol—Insomnia—Everolimus—kidney cancer	0.00333	0.00437	CcSEcCtD
Methocarbamol—Pruritus—Pazopanib—kidney cancer	0.0033	0.00433	CcSEcCtD
Methocarbamol—Somnolence—Everolimus—kidney cancer	0.00327	0.0043	CcSEcCtD
Methocarbamol—Dizziness—Temsirolimus—kidney cancer	0.00327	0.0043	CcSEcCtD
Methocarbamol—Convulsion—Sunitinib—kidney cancer	0.00326	0.00429	CcSEcCtD
Methocarbamol—Dyspepsia—Everolimus—kidney cancer	0.00324	0.00425	CcSEcCtD
Methocarbamol—Insomnia—Erlotinib—kidney cancer	0.00321	0.00422	CcSEcCtD
Methocarbamol—Anaphylactic shock—Sorafenib—kidney cancer	0.00319	0.0042	CcSEcCtD
Methocarbamol—Leukopenia—Dactinomycin—kidney cancer	0.00319	0.00419	CcSEcCtD
Methocarbamol—Pain—Vinblastine—kidney cancer	0.00316	0.00415	CcSEcCtD
Methocarbamol—Conjunctivitis—Paclitaxel—kidney cancer	0.00314	0.00413	CcSEcCtD
Methocarbamol—Pain—Everolimus—kidney cancer	0.00314	0.00413	CcSEcCtD
Methocarbamol—Vomiting—Temsirolimus—kidney cancer	0.00314	0.00413	CcSEcCtD
Methocarbamol—Shock—Sorafenib—kidney cancer	0.00314	0.00413	CcSEcCtD
Methocarbamol—Dyspepsia—Erlotinib—kidney cancer	0.00312	0.0041	CcSEcCtD
Methocarbamol—Rash—Temsirolimus—kidney cancer	0.00312	0.0041	CcSEcCtD
Methocarbamol—Coordination abnormal—Doxorubicin—kidney cancer	0.00312	0.00409	CcSEcCtD
Methocarbamol—Dermatitis—Temsirolimus—kidney cancer	0.00311	0.00409	CcSEcCtD
Methocarbamol—Carvedilol—PTGS1—kidney cancer	0.00311	0.0994	CrCbGaD
Methocarbamol—Headache—Temsirolimus—kidney cancer	0.0031	0.00407	CcSEcCtD
Methocarbamol—Dizziness—Pazopanib—kidney cancer	0.00308	0.00405	CcSEcCtD
Methocarbamol—Feeling abnormal—Vinblastine—kidney cancer	0.00304	0.004	CcSEcCtD
Methocarbamol—Pain—Erlotinib—kidney cancer	0.00303	0.00399	CcSEcCtD
Methocarbamol—Feeling abnormal—Everolimus—kidney cancer	0.00303	0.00398	CcSEcCtD
Methocarbamol—Shock—Sunitinib—kidney cancer	0.00302	0.00397	CcSEcCtD
Methocarbamol—Vomiting—Pazopanib—kidney cancer	0.00296	0.00389	CcSEcCtD
Methocarbamol—Bradycardia—Paclitaxel—kidney cancer	0.00296	0.00389	CcSEcCtD
Methocarbamol—Rash—Pazopanib—kidney cancer	0.00294	0.00386	CcSEcCtD
Methocarbamol—Nausea—Temsirolimus—kidney cancer	0.00294	0.00386	CcSEcCtD
Methocarbamol—Dermatitis—Pazopanib—kidney cancer	0.00293	0.00386	CcSEcCtD
Methocarbamol—Headache—Pazopanib—kidney cancer	0.00292	0.00383	CcSEcCtD
Methocarbamol—Body temperature increased—Everolimus—kidney cancer	0.00291	0.00382	CcSEcCtD
Methocarbamol—Vertigo—Vincristine—kidney cancer	0.00286	0.00376	CcSEcCtD
Methocarbamol—Leukopenia—Vincristine—kidney cancer	0.00285	0.00374	CcSEcCtD
Methocarbamol—Carvedilol—CYP1A1—kidney cancer	0.00285	0.0909	CrCbGaD
Methocarbamol—Dyspepsia—Sorafenib—kidney cancer	0.00281	0.00369	CcSEcCtD
Methocarbamol—Body temperature increased—Erlotinib—kidney cancer	0.0028	0.00369	CcSEcCtD
Methocarbamol—CA1—C-MYB transcription factor network—KIT—kidney cancer	0.00279	0.0134	CbGpPWpGaD
Methocarbamol—Insomnia—Sunitinib—kidney cancer	0.00278	0.00365	CcSEcCtD
Methocarbamol—Nausea—Pazopanib—kidney cancer	0.00277	0.00364	CcSEcCtD
Methocarbamol—Convulsion—Vincristine—kidney cancer	0.00276	0.00362	CcSEcCtD
Methocarbamol—Pain—Sorafenib—kidney cancer	0.00273	0.00359	CcSEcCtD
Methocarbamol—Hypersensitivity—Vinblastine—kidney cancer	0.00272	0.00357	CcSEcCtD
Methocarbamol—Hypersensitivity—Everolimus—kidney cancer	0.00271	0.00356	CcSEcCtD
Methocarbamol—Dyspepsia—Sunitinib—kidney cancer	0.0027	0.00355	CcSEcCtD
Methocarbamol—Leukopenia—Gemcitabine—kidney cancer	0.0027	0.00355	CcSEcCtD
Methocarbamol—Flushing—Paclitaxel—kidney cancer	0.0027	0.00354	CcSEcCtD
Methocarbamol—Pain—Sunitinib—kidney cancer	0.00263	0.00345	CcSEcCtD
Methocarbamol—Pruritus—Everolimus—kidney cancer	0.0026	0.00342	CcSEcCtD
Methocarbamol—Anaphylactic shock—Vincristine—kidney cancer	0.0026	0.00341	CcSEcCtD
Methocarbamol—Jaundice—Capecitabine—kidney cancer	0.00259	0.0034	CcSEcCtD
Methocarbamol—Conjunctivitis—Capecitabine—kidney cancer	0.00258	0.00339	CcSEcCtD
Methocarbamol—Thrombophlebitis—Doxorubicin—kidney cancer	0.00257	0.00337	CcSEcCtD
Methocarbamol—Urticaria—Sorafenib—kidney cancer	0.00254	0.00333	CcSEcCtD
Methocarbamol—Body temperature increased—Sorafenib—kidney cancer	0.00252	0.00332	CcSEcCtD
Methocarbamol—Pruritus—Erlotinib—kidney cancer	0.00251	0.0033	CcSEcCtD
Methocarbamol—Pain—Dactinomycin—kidney cancer	0.00249	0.00327	CcSEcCtD
Methocarbamol—Dysgeusia—Paclitaxel—kidney cancer	0.00248	0.00325	CcSEcCtD
Methocarbamol—Anaphylactic shock—Gemcitabine—kidney cancer	0.00246	0.00324	CcSEcCtD
Methocarbamol—Dizziness—Vinblastine—kidney cancer	0.00244	0.00321	CcSEcCtD
Methocarbamol—Dizziness—Everolimus—kidney cancer	0.00243	0.0032	CcSEcCtD
Methocarbamol—Body temperature increased—Sunitinib—kidney cancer	0.00243	0.00319	CcSEcCtD
Methocarbamol—Hypotension—Vincristine—kidney cancer	0.00243	0.00319	CcSEcCtD
Methocarbamol—Bradycardia—Capecitabine—kidney cancer	0.00243	0.00319	CcSEcCtD
Methocarbamol—Feeling abnormal—Dactinomycin—kidney cancer	0.0024	0.00315	CcSEcCtD
Methocarbamol—Vision blurred—Paclitaxel—kidney cancer	0.00238	0.00313	CcSEcCtD
Methocarbamol—Hypersensitivity—Sorafenib—kidney cancer	0.00235	0.00309	CcSEcCtD
Methocarbamol—Insomnia—Vincristine—kidney cancer	0.00235	0.00309	CcSEcCtD
Methocarbamol—Vomiting—Vinblastine—kidney cancer	0.00235	0.00308	CcSEcCtD
Methocarbamol—Dizziness—Erlotinib—kidney cancer	0.00235	0.00308	CcSEcCtD
Methocarbamol—Vomiting—Everolimus—kidney cancer	0.00234	0.00307	CcSEcCtD
Methocarbamol—Rash—Everolimus—kidney cancer	0.00232	0.00305	CcSEcCtD
Methocarbamol—Dermatitis—Everolimus—kidney cancer	0.00232	0.00304	CcSEcCtD
Methocarbamol—Headache—Vinblastine—kidney cancer	0.00231	0.00304	CcSEcCtD
Methocarbamol—Angioedema—Paclitaxel—kidney cancer	0.00231	0.00304	CcSEcCtD
Methocarbamol—Headache—Everolimus—kidney cancer	0.0023	0.00303	CcSEcCtD
Methocarbamol—Hypotension—Gemcitabine—kidney cancer	0.0023	0.00303	CcSEcCtD
Methocarbamol—Body temperature increased—Dactinomycin—kidney cancer	0.0023	0.00302	CcSEcCtD
Methocarbamol—Vertigo—Paclitaxel—kidney cancer	0.00227	0.00299	CcSEcCtD
Methocarbamol—CA1—C-MYB transcription factor network—CDKN2A—kidney cancer	0.00227	0.0109	CbGpPWpGaD
Methocarbamol—Syncope—Paclitaxel—kidney cancer	0.00227	0.00298	CcSEcCtD
Methocarbamol—Leukopenia—Paclitaxel—kidney cancer	0.00226	0.00297	CcSEcCtD
Methocarbamol—Hypersensitivity—Sunitinib—kidney cancer	0.00226	0.00297	CcSEcCtD
Methocarbamol—Pruritus—Sorafenib—kidney cancer	0.00226	0.00297	CcSEcCtD
Methocarbamol—Vomiting—Erlotinib—kidney cancer	0.00226	0.00296	CcSEcCtD
Methocarbamol—Rash—Erlotinib—kidney cancer	0.00224	0.00294	CcSEcCtD
Methocarbamol—Dermatitis—Erlotinib—kidney cancer	0.00224	0.00294	CcSEcCtD
Methocarbamol—Insomnia—Gemcitabine—kidney cancer	0.00223	0.00293	CcSEcCtD
Methocarbamol—Headache—Erlotinib—kidney cancer	0.00222	0.00292	CcSEcCtD
Methocarbamol—Loss of consciousness—Paclitaxel—kidney cancer	0.00222	0.00292	CcSEcCtD
Methocarbamol—Pain—Vincristine—kidney cancer	0.00222	0.00292	CcSEcCtD
Methocarbamol—Diplopia—Doxorubicin—kidney cancer	0.00222	0.00292	CcSEcCtD
Methocarbamol—Flushing—Capecitabine—kidney cancer	0.00221	0.00291	CcSEcCtD
Methocarbamol—Nausea—Vinblastine—kidney cancer	0.00219	0.00288	CcSEcCtD
Methocarbamol—Somnolence—Gemcitabine—kidney cancer	0.00219	0.00288	CcSEcCtD
Methocarbamol—Convulsion—Paclitaxel—kidney cancer	0.00219	0.00288	CcSEcCtD
Methocarbamol—Nausea—Everolimus—kidney cancer	0.00218	0.00287	CcSEcCtD
Methocarbamol—Pruritus—Sunitinib—kidney cancer	0.00217	0.00286	CcSEcCtD
Methocarbamol—Propranolol—CYP1A1—kidney cancer	0.00216	0.0691	CrCbGaD
Methocarbamol—Hypersensitivity—Dactinomycin—kidney cancer	0.00214	0.00282	CcSEcCtD
Methocarbamol—CA1—C-MYB transcription factor network—CD4—kidney cancer	0.00214	0.0103	CbGpPWpGaD
Methocarbamol—CA1—C-MYB transcription factor network—PTGS2—kidney cancer	0.00212	0.0102	CbGpPWpGaD
Methocarbamol—Dizziness—Sorafenib—kidney cancer	0.00211	0.00277	CcSEcCtD
Methocarbamol—Pain—Gemcitabine—kidney cancer	0.00211	0.00277	CcSEcCtD
Methocarbamol—Nausea—Erlotinib—kidney cancer	0.00211	0.00277	CcSEcCtD
Methocarbamol—Confusional state—Paclitaxel—kidney cancer	0.00208	0.00273	CcSEcCtD
Methocarbamol—Anaphylactic shock—Paclitaxel—kidney cancer	0.00206	0.00271	CcSEcCtD
Methocarbamol—Body temperature increased—Vincristine—kidney cancer	0.00205	0.0027	CcSEcCtD
Methocarbamol—Dysgeusia—Capecitabine—kidney cancer	0.00203	0.00267	CcSEcCtD
Methocarbamol—Dizziness—Sunitinib—kidney cancer	0.00203	0.00267	CcSEcCtD
Methocarbamol—Feeling abnormal—Gemcitabine—kidney cancer	0.00203	0.00267	CcSEcCtD
Methocarbamol—Shock—Paclitaxel—kidney cancer	0.00203	0.00267	CcSEcCtD
Methocarbamol—Vomiting—Sorafenib—kidney cancer	0.00203	0.00267	CcSEcCtD
Methocarbamol—Rash—Sorafenib—kidney cancer	0.00201	0.00265	CcSEcCtD
Methocarbamol—Dermatitis—Sorafenib—kidney cancer	0.00201	0.00264	CcSEcCtD
Methocarbamol—CA1—C-MYB transcription factor network—CDKN1B—kidney cancer	0.00201	0.00967	CbGpPWpGaD
Methocarbamol—Headache—Sorafenib—kidney cancer	0.002	0.00263	CcSEcCtD
Methocarbamol—Vision blurred—Capecitabine—kidney cancer	0.00196	0.00257	CcSEcCtD
Methocarbamol—Vomiting—Sunitinib—kidney cancer	0.00195	0.00257	CcSEcCtD
Methocarbamol—Body temperature increased—Gemcitabine—kidney cancer	0.00195	0.00256	CcSEcCtD
Methocarbamol—Rash—Sunitinib—kidney cancer	0.00194	0.00255	CcSEcCtD
Methocarbamol—Dermatitis—Sunitinib—kidney cancer	0.00193	0.00254	CcSEcCtD
Methocarbamol—Hypotension—Paclitaxel—kidney cancer	0.00193	0.00253	CcSEcCtD
Methocarbamol—Headache—Sunitinib—kidney cancer	0.00192	0.00253	CcSEcCtD
Methocarbamol—CA1—C-MYB transcription factor network—CCND1—kidney cancer	0.00192	0.00922	CbGpPWpGaD
Methocarbamol—Hypersensitivity—Vincristine—kidney cancer	0.00191	0.00252	CcSEcCtD
Methocarbamol—Nausea—Sorafenib—kidney cancer	0.0019	0.00249	CcSEcCtD
Methocarbamol—Insomnia—Paclitaxel—kidney cancer	0.00187	0.00245	CcSEcCtD
Methocarbamol—Vertigo—Capecitabine—kidney cancer	0.00186	0.00245	CcSEcCtD
Methocarbamol—Syncope—Capecitabine—kidney cancer	0.00186	0.00245	CcSEcCtD
Methocarbamol—Leukopenia—Capecitabine—kidney cancer	0.00186	0.00244	CcSEcCtD
Methocarbamol—Vomiting—Dactinomycin—kidney cancer	0.00185	0.00243	CcSEcCtD
Methocarbamol—Somnolence—Paclitaxel—kidney cancer	0.00183	0.00241	CcSEcCtD
Methocarbamol—Rash—Dactinomycin—kidney cancer	0.00183	0.00241	CcSEcCtD
Methocarbamol—Nausea—Sunitinib—kidney cancer	0.00182	0.0024	CcSEcCtD
Methocarbamol—Loss of consciousness—Capecitabine—kidney cancer	0.00182	0.0024	CcSEcCtD
Methocarbamol—Dyspepsia—Paclitaxel—kidney cancer	0.00182	0.00239	CcSEcCtD
Methocarbamol—CA1—Metabolism—ACY1—kidney cancer	0.00177	0.00851	CbGpPWpGaD
Methocarbamol—Pain—Paclitaxel—kidney cancer	0.00176	0.00232	CcSEcCtD
Methocarbamol—Pruritus—Gemcitabine—kidney cancer	0.00174	0.00229	CcSEcCtD
Methocarbamol—Nausea—Dactinomycin—kidney cancer	0.00173	0.00227	CcSEcCtD
Methocarbamol—Dizziness—Vincristine—kidney cancer	0.00172	0.00226	CcSEcCtD
Methocarbamol—Drowsiness—Doxorubicin—kidney cancer	0.00171	0.00225	CcSEcCtD
Methocarbamol—Confusional state—Capecitabine—kidney cancer	0.00171	0.00224	CcSEcCtD
Methocarbamol—Feeling abnormal—Paclitaxel—kidney cancer	0.0017	0.00223	CcSEcCtD
Methocarbamol—Jaundice—Doxorubicin—kidney cancer	0.00167	0.00219	CcSEcCtD
Methocarbamol—Shock—Capecitabine—kidney cancer	0.00167	0.00219	CcSEcCtD
Methocarbamol—Conjunctivitis—Doxorubicin—kidney cancer	0.00166	0.00219	CcSEcCtD
Methocarbamol—Vomiting—Vincristine—kidney cancer	0.00165	0.00217	CcSEcCtD
Methocarbamol—Urticaria—Paclitaxel—kidney cancer	0.00164	0.00215	CcSEcCtD
Methocarbamol—Rash—Vincristine—kidney cancer	0.00164	0.00215	CcSEcCtD
Methocarbamol—Dermatitis—Vincristine—kidney cancer	0.00164	0.00215	CcSEcCtD
Methocarbamol—Body temperature increased—Paclitaxel—kidney cancer	0.00163	0.00214	CcSEcCtD
Methocarbamol—Headache—Vincristine—kidney cancer	0.00163	0.00214	CcSEcCtD
Methocarbamol—Hypotension—Capecitabine—kidney cancer	0.00158	0.00208	CcSEcCtD
Methocarbamol—Vomiting—Gemcitabine—kidney cancer	0.00157	0.00206	CcSEcCtD
Methocarbamol—Bradycardia—Doxorubicin—kidney cancer	0.00156	0.00206	CcSEcCtD
Methocarbamol—Rash—Gemcitabine—kidney cancer	0.00155	0.00204	CcSEcCtD
Methocarbamol—Dermatitis—Gemcitabine—kidney cancer	0.00155	0.00204	CcSEcCtD
Methocarbamol—Headache—Gemcitabine—kidney cancer	0.00154	0.00203	CcSEcCtD
Methocarbamol—Nausea—Vincristine—kidney cancer	0.00154	0.00203	CcSEcCtD
Methocarbamol—CA1—C-MYB transcription factor network—MYC—kidney cancer	0.00154	0.0074	CbGpPWpGaD
Methocarbamol—Insomnia—Capecitabine—kidney cancer	0.00153	0.00201	CcSEcCtD
Methocarbamol—Hypersensitivity—Paclitaxel—kidney cancer	0.00152	0.002	CcSEcCtD
Methocarbamol—Carvedilol—ABCB1—kidney cancer	0.00151	0.0483	CrCbGaD
Methocarbamol—CA1—Metabolism—PDHB—kidney cancer	0.0015	0.00724	CbGpPWpGaD
Methocarbamol—Dyspepsia—Capecitabine—kidney cancer	0.00149	0.00196	CcSEcCtD
Methocarbamol—Nausea—Gemcitabine—kidney cancer	0.00146	0.00192	CcSEcCtD
Methocarbamol—Pruritus—Paclitaxel—kidney cancer	0.00146	0.00192	CcSEcCtD
Methocarbamol—Pain—Capecitabine—kidney cancer	0.00145	0.0019	CcSEcCtD
Methocarbamol—Flushing—Doxorubicin—kidney cancer	0.00143	0.00187	CcSEcCtD
Methocarbamol—CA1—C-MYB transcription factor network—KRAS—kidney cancer	0.00142	0.00684	CbGpPWpGaD
Methocarbamol—CA1—Metabolism—CCBL1—kidney cancer	0.00141	0.0068	CbGpPWpGaD
Methocarbamol—Feeling abnormal—Capecitabine—kidney cancer	0.0014	0.00183	CcSEcCtD
Methocarbamol—Dizziness—Paclitaxel—kidney cancer	0.00136	0.00179	CcSEcCtD
Methocarbamol—Urticaria—Capecitabine—kidney cancer	0.00135	0.00177	CcSEcCtD
Methocarbamol—Body temperature increased—Capecitabine—kidney cancer	0.00134	0.00176	CcSEcCtD
Methocarbamol—Vomiting—Paclitaxel—kidney cancer	0.00131	0.00172	CcSEcCtD
Methocarbamol—Dysgeusia—Doxorubicin—kidney cancer	0.00131	0.00172	CcSEcCtD
Methocarbamol—Rash—Paclitaxel—kidney cancer	0.0013	0.00171	CcSEcCtD
Methocarbamol—Dermatitis—Paclitaxel—kidney cancer	0.0013	0.00171	CcSEcCtD
Methocarbamol—Headache—Paclitaxel—kidney cancer	0.00129	0.0017	CcSEcCtD
Methocarbamol—Vision blurred—Doxorubicin—kidney cancer	0.00126	0.00166	CcSEcCtD
Methocarbamol—Hypersensitivity—Capecitabine—kidney cancer	0.00125	0.00164	CcSEcCtD
Methocarbamol—CA1—Metabolism—GLIPR1—kidney cancer	0.00123	0.0059	CbGpPWpGaD
Methocarbamol—CA1—Metabolism—PPAT—kidney cancer	0.00123	0.0059	CbGpPWpGaD
Methocarbamol—Nausea—Paclitaxel—kidney cancer	0.00123	0.00161	CcSEcCtD
Methocarbamol—Vertigo—Doxorubicin—kidney cancer	0.0012	0.00158	CcSEcCtD
Methocarbamol—Syncope—Doxorubicin—kidney cancer	0.0012	0.00158	CcSEcCtD
Methocarbamol—Pruritus—Capecitabine—kidney cancer	0.0012	0.00157	CcSEcCtD
Methocarbamol—Leukopenia—Doxorubicin—kidney cancer	0.0012	0.00157	CcSEcCtD
Methocarbamol—Loss of consciousness—Doxorubicin—kidney cancer	0.00118	0.00154	CcSEcCtD
Methocarbamol—Convulsion—Doxorubicin—kidney cancer	0.00116	0.00152	CcSEcCtD
Methocarbamol—Propranolol—ABCB1—kidney cancer	0.00115	0.0367	CrCbGaD
Methocarbamol—CA1—Metabolism—APRT—kidney cancer	0.00114	0.00548	CbGpPWpGaD
Methocarbamol—CA1—Metabolism—FH—kidney cancer	0.00114	0.00548	CbGpPWpGaD
Methocarbamol—Dizziness—Capecitabine—kidney cancer	0.00112	0.00147	CcSEcCtD
Methocarbamol—Confusional state—Doxorubicin—kidney cancer	0.0011	0.00145	CcSEcCtD
Methocarbamol—Anaphylactic shock—Doxorubicin—kidney cancer	0.00109	0.00143	CcSEcCtD
Methocarbamol—Vomiting—Capecitabine—kidney cancer	0.00108	0.00141	CcSEcCtD
Methocarbamol—Shock—Doxorubicin—kidney cancer	0.00107	0.00141	CcSEcCtD
Methocarbamol—CA1—Metabolism—GPC3—kidney cancer	0.00107	0.00516	CbGpPWpGaD
Methocarbamol—Rash—Capecitabine—kidney cancer	0.00107	0.0014	CcSEcCtD
Methocarbamol—Dermatitis—Capecitabine—kidney cancer	0.00107	0.0014	CcSEcCtD
Methocarbamol—Headache—Capecitabine—kidney cancer	0.00106	0.00139	CcSEcCtD
Methocarbamol—CA1—Metabolism—CA2—kidney cancer	0.00104	0.00502	CbGpPWpGaD
Methocarbamol—Hypotension—Doxorubicin—kidney cancer	0.00102	0.00134	CcSEcCtD
Methocarbamol—CA1—Metabolism—ALAD—kidney cancer	0.00102	0.00489	CbGpPWpGaD
Methocarbamol—Nausea—Capecitabine—kidney cancer	0.00101	0.00132	CcSEcCtD
Methocarbamol—CA1—Metabolism—ST3GAL2—kidney cancer	0.000991	0.00477	CbGpPWpGaD
Methocarbamol—Insomnia—Doxorubicin—kidney cancer	0.000987	0.0013	CcSEcCtD
Methocarbamol—Somnolence—Doxorubicin—kidney cancer	0.00097	0.00128	CcSEcCtD
Methocarbamol—CA1—Metabolism—ALDH1A1—kidney cancer	0.000969	0.00466	CbGpPWpGaD
Methocarbamol—Dyspepsia—Doxorubicin—kidney cancer	0.000961	0.00126	CcSEcCtD
Methocarbamol—Pain—Doxorubicin—kidney cancer	0.000933	0.00123	CcSEcCtD
Methocarbamol—CA1—Metabolism—SLC5A3—kidney cancer	0.000929	0.00447	CbGpPWpGaD
Methocarbamol—CA1—Metabolism—PGK1—kidney cancer	0.000929	0.00447	CbGpPWpGaD
Methocarbamol—CA1—Metabolism—LDHB—kidney cancer	0.000911	0.00438	CbGpPWpGaD
Methocarbamol—Feeling abnormal—Doxorubicin—kidney cancer	0.000899	0.00118	CcSEcCtD
Methocarbamol—Urticaria—Doxorubicin—kidney cancer	0.000867	0.00114	CcSEcCtD
Methocarbamol—Body temperature increased—Doxorubicin—kidney cancer	0.000863	0.00113	CcSEcCtD
Methocarbamol—Hypersensitivity—Doxorubicin—kidney cancer	0.000804	0.00106	CcSEcCtD
Methocarbamol—CA1—Metabolism—CA9—kidney cancer	0.00079	0.0038	CbGpPWpGaD
Methocarbamol—Pruritus—Doxorubicin—kidney cancer	0.000772	0.00101	CcSEcCtD
Methocarbamol—Dizziness—Doxorubicin—kidney cancer	0.000722	0.000949	CcSEcCtD
Methocarbamol—Vomiting—Doxorubicin—kidney cancer	0.000694	0.000912	CcSEcCtD
Methocarbamol—Rash—Doxorubicin—kidney cancer	0.000688	0.000904	CcSEcCtD
Methocarbamol—Dermatitis—Doxorubicin—kidney cancer	0.000688	0.000904	CcSEcCtD
Methocarbamol—Headache—Doxorubicin—kidney cancer	0.000684	0.000899	CcSEcCtD
Methocarbamol—CA1—Metabolism—CRABP1—kidney cancer	0.000672	0.00323	CbGpPWpGaD
Methocarbamol—Nausea—Doxorubicin—kidney cancer	0.000648	0.000852	CcSEcCtD
Methocarbamol—CA1—Metabolism—ITPR2—kidney cancer	0.000624	0.00301	CbGpPWpGaD
Methocarbamol—CA1—Metabolism—GSTT1—kidney cancer	0.000569	0.00274	CbGpPWpGaD
Methocarbamol—CA1—Metabolism—ACHE—kidney cancer	0.000569	0.00274	CbGpPWpGaD
Methocarbamol—CA1—Metabolism—SCARB1—kidney cancer	0.000539	0.00259	CbGpPWpGaD
Methocarbamol—CA1—Metabolism—PTGS1—kidney cancer	0.000534	0.00257	CbGpPWpGaD
Methocarbamol—CA1—Metabolism—PSMD7—kidney cancer	0.000523	0.00252	CbGpPWpGaD
Methocarbamol—CA1—Metabolism—BCHE—kidney cancer	0.000496	0.00239	CbGpPWpGaD
Methocarbamol—CA1—Metabolism—SLC5A5—kidney cancer	0.00049	0.00236	CbGpPWpGaD
Methocarbamol—CA1—Metabolism—SLC2A1—kidney cancer	0.000473	0.00228	CbGpPWpGaD
Methocarbamol—CA1—Metabolism—GSTP1—kidney cancer	0.000395	0.0019	CbGpPWpGaD
Methocarbamol—CA1—Metabolism—ABCB1—kidney cancer	0.000374	0.0018	CbGpPWpGaD
Methocarbamol—CA1—Metabolism—GSTM1—kidney cancer	0.000363	0.00175	CbGpPWpGaD
Methocarbamol—CA1—Metabolism—CYP1A1—kidney cancer	0.000344	0.00165	CbGpPWpGaD
Methocarbamol—CA1—Metabolism—POMC—kidney cancer	0.000256	0.00123	CbGpPWpGaD
Methocarbamol—CA1—Metabolism—PTGS2—kidney cancer	0.000204	0.000984	CbGpPWpGaD
Methocarbamol—CA1—Metabolism—PTEN—kidney cancer	0.000178	0.000858	CbGpPWpGaD
Methocarbamol—CA1—Metabolism—PIK3CA—kidney cancer	0.000126	0.000605	CbGpPWpGaD
